Dose‐dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects

Figures & data

Table I. Clinical characteristics of the patients at the time of randomization (mean ± SD).

	Placebo	Low dose	Medium dose	High dose
Age (years)	59±7	58±8	58±7	60±7
Gender (M/F)	22/19	22/20	26/16	21/20
Weight (kg)	79±13	77±12	81±13	79±12
SBP (mmHg)	148±13	147±12	146±14	149±15
DBP (mmHg)	85±9	85±7	85±10	85±10
HR (beats/min)	68±9	69±9	70±10	67±7
Serum creatinine (μmol/l)	79±13	79±13	80±13	79±12
Plasma ACE (U/l)	17.0±5.2	16.2±4.6	16.9±4.8	17.2±4.6
UnaV (mmol/24 h)	175±65	154±48	164±60	180±92

M, male; F, female; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ACE, angiotensin-converting enzyme; UnaV, urinary sodium excretion.

Figure 1. Time course of blood pressure during the various phases of the trial. SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LTP, Lactotripeptides.

Figure 2. Time course of blood pressure during the various phases of the trial. SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LTP, Lactotripeptides.